A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492
Phase 1
72
about 2.1 years
18–70
5 sites in AL, CA, IA
About this study
Researchers are testing the safety, tolerability, how your body processes (pharmacokinetics), and how the drug affects your body (pharmacodynamics) of a medication called AZD5492. The trial will last for about 782 days and involve adults with conditions like lupus, inflammatory myopathies, or rheumatoid arthritis.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AZD5492
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Safety evaluation of AZD5492: Number of SAEs leading to death, Safety evaluation of AZD5492: Number of participants with related treatment-emergent adverse events., Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events by grade., Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events., Tolerability evaluation of AZD5492: Number of participants with abnormal ECG., Tolerability evaluation of AZD5492: Number of participants with treatment-emergent clinical laboratory abnormalities., Tolerability evaluation of AZD5492: Number of participants with treatment-emergent vital signs abnormalities.
Secondary: Serum Pharmacokinetics (PK) parameters of AZD5492 (AUC), Serum Pharmacokinetics (PK) parameters of AZD5492 (AUClast), Serum Pharmacokinetics (PK) parameters of AZD5492 (Cmax), Serum Pharmacokinetics (PK) parameters of AZD5492 (t1/2λz)
Immune